Relationship of p21WAF-1 protein expression with prognosis in advanced prostate cancer treated by androgen ablation

Prostate

Volumn 49, Issue 3, 2001, Pages 191-199

  Omar, Eltaher A ^a   Behlouli, Hassan ^a   Chevalier, Simone ^a   Aprikian, Armen G ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Androgen ablation; Immunohistochemistry; p21; p53; Prostate cancer; Survival

Indexed keywords

ANTIANDROGEN; PROTEIN P21; PROTEIN P53;

ARTICLE; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CORRELATION FUNCTION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION;

AGED; ANDROGEN ANTAGONISTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035153549     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.1134     Document Type: Article

References (45)

1. Long-term outcome in patients with pTxN+ adenocarcinoma of the prostate treated with radical prostatectomy and early androgen ablation
2. Prognostic factors in men with stage D1 prostate cancer: Identification of patients less likely to have prolonged survival after radical prostatectomy
3. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan
4. P53 mutations in human cancers
5. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression
6. Overexpression of p53 and prognosis in breast cancer
7. Clinical implications of p53: Effect on prognosis, tumour progression and chemotherapy response
8. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma
9. P53 protein accumulation and gene mutation in the progression of human prostatic carcinoma
10. P53 gene alterations in human prostate carcinoma
11. Outcome prediction with p53 immunostaining after radical prostatectomy in patients with locally advanced prostate cancer
12. Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy
13. P53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: A molecular and immunohstochemical analysis
14. P53 nuclear protein expression is an independent prognostic factor in clinically localized prostate cancer patients undergoing radical prostatectomy
15. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy
16. Prognostic significance of Ki-67 expression in advanced prostate cancers in relation to disease progression after androgen ablation
17. Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: A retrospective immunohistochemical analysis
18. P53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy
19. Cell cycle control and cancer
20. P21 is a universal inhibitor of cyclin kinases
21. WAF1, a potential mediator of p53 tumor suppression
22. WAF1/CIP1 is induced in p53 mediated G1 arrest and apoptosis
23. Induction of WAF1/CIP1 by a p53-independent pathway
24. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53 independent mechanism
25. The clinical significance of p21waf1/cip1 and p53 expression in pancreatic adenocarcinoma
26. P53 and p21 waf1/cip1/sdi1 gene products in barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction
27. Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma
28. Expression of p21 and mutant gene products in residual prostatic tumor cells after radical radiotherapy
29. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer
30. Proliferation and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: Prognostic significance of p21/WAF1/CIP1 expression
31. Abnormal p53 expression is rare in clinically localized prostate cancer: Comparison between immunohistochemical and molecular detection of p53 mutations
32. Frequency and characterization of p53 mutations in clinically localized prostate cancer
33. P53 is mutated in a subset of advanced-stage prostate cancers
34. P53 oncogene mutations in human prostate cancer specimens
35. P53, bcl-2 retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate
36. Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma
37. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer
38. Prognostic value of p21 wafl and p53 expression in breast carcinoma: An immunohistochemical study in 261 patients with long-term follow-up
39. P21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma
40. Somatic mutation of the WAF1/CIP1 gene in primary prostate cancer
41. A clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers
42. Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma
43. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma
44. Relationship of p21(WAF1) expression with disease-free survival and biochemical recurrence in prostate adenocarcinoma
45. Expression of P21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy